Company intelligence / Profile preview

PURE+

Ownership: Private
Development stage: Other

Overview

PURE Bioscience has developed a proprietary antimicrobial platform based on Silver Dihydrogen Citrate. Their SDC-based products are broad-spectrum antimicrobials that are non-toxic and have regulatory approval for use as disinfectants and sanitizers in food safety and other industries. The company manufactures both finished products and raw material ingredients for personal care product manufacturers. No clinical trial results reported as their primary applications are not pharmaceutical therapeutics but health/environmental hygiene.

Therapeutic areas: Infectious Diseases
Modalities: Small moleculeDevice
Industry: Chemicals & Materials

Partnerships

Not specified in available sources; company does sell to manufacturers of personal care products.

Beyond the preview

Go deeper on PURE+.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PURE+.

Explore the full profile